Showing results (191-200 of 268) with videos related to
Sort By:
Pageof 27
Carbohydrate Polymers|August 31, 2013
Using high pressure processing (HPP) to pretreat sugarcane bagasseJ F Castañón-Rodríguez, B Torrestiana-Sánchez, M Montero-Lagunes, et al.AIDS (London, England)|August 28, 1999
Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replicationF García, G Niebla, J Romeu, et al.Journal of Viral Hepatitis|November 4, 2014
Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in SpainS Serrano-Villar, P Sobrino-Vegas, S Monge, et al.Antiviral Therapy|April 1, 1997
Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3A Ibáñez, J Peraire, A Arnó, et al.Journal of Virological Methods|August 15, 1998
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutationsJ C Schmit, L Ruiz, L Stuyver, et al.The Journal of Antimicrobial Chemotherapy|February 7, 2013
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudineJ I Bernardino, F Pulido, E Martinez, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 10, 2016
Empirical monotherapy with meropenem or combination therapy: the microbiological point of viewP Garcinuño, M Santibañez, L Gimeno, et al.HIV Medicine|March 4, 2016
Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapyV Estrada, S Monge, M D Gómez-Garre, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 21, 2001
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled studyL Ruiz, E Negredo, P Domingo, et al.Molecular Pharmacology|March 14, 1998
Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir)J A Esté, C Cabrera, D Schols, et al.Pageof 27